Skip to main content

Pyoderma Gangrenosum

7
Pipeline Programs
8
Companies
10
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
4
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
982%
Small Molecule
218%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
258M Part D

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
1
adalimumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03311464Completed22Est. Apr 2020
Sandoz
SandozAustria - Kundl
2 programs
1
1
secukinumab 150 mgPhase 21 trial
SecukinumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT02733094Completed8Est. Sep 2019
NCT04274166Withdrawn0Est. Apr 2022
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
2 programs
2
BaricitinibPhase 2Small Molecule1 trial
GuselkumabPhase 2Monoclonal Antibody
Active Trials
NCT04901325Completed5Est. May 2025
Prevail Therapeutics
1 program
1
IxekizumabPhase 2Monoclonal Antibody
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
SpesolimabPHASE_2Monoclonal Antibody1 trial
SpesolimabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT06092216Terminated5Est. Jan 2025
NCT06624670Recruiting90Est. Aug 2028
InflaRx
InflaRxJENA, Germany
2 programs
vilobelimabPHASE_2Monoclonal Antibody1 trial
vilobelimabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT03971643Completed19Est. Jan 2022
NCT05964413Terminated54Est. Jul 2025
Bristol Myers Squibb
1 program
DeucravacitinibPHASE_1Small Molecule1 trial
Active Trials
NCT05821374Withdrawn0Est. Apr 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
IxekizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT03137160Completed4Est. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boehringer IngelheimSpesolimab
InflaRxvilobelimab
AbbVieadalimumab
Oregon TherapeuticsBaricitinib
Boehringer IngelheimSpesolimab
Sandozsecukinumab 150 mg
InflaRxvilobelimab
Eli Lilly and CompanyIxekizumab
SandozSecukinumab
Bristol Myers SquibbDeucravacitinib

Clinical Trials (10)

Total enrollment: 207 patients across 10 trials

NCT06624670Boehringer IngelheimSpesolimab

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Start: Feb 2025Est. completion: Aug 202890 patients
Phase 3Recruiting
NCT05964413InflaRxvilobelimab

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Start: Nov 2023Est. completion: Jul 202554 patients
Phase 3Terminated
NCT03311464AbbVieadalimumab

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Start: Oct 2017Est. completion: Apr 202022 patients
Phase 3Completed
NCT04901325Oregon TherapeuticsBaricitinib

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Start: Oct 2023Est. completion: May 20255 patients
Phase 2Completed
NCT06092216Boehringer IngelheimSpesolimab

Spesolimab in Pyoderma Gangrenosum

Start: Sep 2023Est. completion: Jan 20255 patients
Phase 2Terminated
NCT04274166Sandozsecukinumab 150 mg

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Start: May 2021Est. completion: Apr 20220
Phase 2Withdrawn
NCT03971643InflaRxvilobelimab

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Start: May 2019Est. completion: Jan 202219 patients
Phase 2Completed
NCT03137160Eli Lilly and CompanyIxekizumab

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Start: May 2017Est. completion: Aug 20184 patients
Phase 2Completed
NCT02733094SandozSecukinumab

Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Start: Apr 2016Est. completion: Sep 20198 patients
Phase 1/2Completed
NCT05821374Bristol Myers SquibbDeucravacitinib

Deucravacitinib in PG

Start: Apr 2024Est. completion: Apr 20240
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 207 patients
Monoclonal Antibody is the dominant modality (82% of programs)
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.